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ABSTRACT 
Objective: Anticonvulsant is one class of drugs often used off-label. This study was conducted to investigate the prevalence and the indication of the 
off-label use of anticonvulsants in a private hospital in Java, Indonesia. 
Methods: This was an observational study with a retrospective data collection in a private hospital in Java. Data were obtained on the prescription 
of anticonvulsants. Indications of the use of anticonvulsants were obtained from the medical records of patients who were prescribed 
anticonvulsants. The off-label use of anticonvulsants was defined a prescribing of medication outside the indication approved by The National 
Agency of Drug and Food Control Indonesia (NA-DFC). The use off-label of anticonvulsants was calculated by descriptive analysis and presented as a 
percentage. 
Results: It showed that in one year there were 5,310 for 1,316 patients: of this 462 patients (35.11%) were for an off-label use. The anticonvulsants 
used off-label were oxcarbazepine 67.27% (37/55), carbamazepine 46.15% (54/117), pregabalin45.45% (60/132), phenytoin37.62% (225/598), 
valproate 25.34% (37/109), and gabapentin 18.28% (49/219). The highest off-label use of anticonvulsants was found in neurological and 
psychiatric disorders 67.32% (n=311), and on 97.19% of them were not supported by strong clinical evidence. 
Conclusion: The off-label use of anticonvulsants occurred in one-third of patients receiving prescriptions of anticonvulsants, even though for most 
of them there was a lack of evidence. More attention must be paid to the efficacy and risk of side effects of the drug used. 
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Off-label prescribing refers to the use of a licensed drug that is 
different from the description in the product information [1] .  
MATERIALS AND METHODS 
According to Stafford (2008), the off-label use of anticonvulsants 
was 74% [2]. Zito et al. (2006) found that anticonvulsants were 
given to children with psychiatric diagnoses without seizures 
(81%), children with a diagnosis of seizures (19%), and children 
with seizures and psychiatric diagnoses (71%) [3]. An 
epidemiological study of the off-label use of anticonvulsants has 
also been carried out by Chen et al. (2005) in the Medicaid 
population of the U. S. state of Georgia. The results showed an 
off-label use of anticonvulsant of as much as 71.3% with 
gabapentin as the most widely prescribed off-label 
anticonvulsant (86%). Four comorbidities of patients receiving 
off-label anticonvulsants are patients with diabetes mellitus, 
depression, schizophrenia, and pain. Neurologists were found to 
be the practitioners who most prescribe off-label anti-
convulsants [4]. 
The off-label drug use is still debatable. This is because some off-
label drug use is not supported by strong evidence. This study 
was conducted to detect the off-label use of anticonvulsant. This 
research is needed as a baseline data on the off-label use of 
anticonvulsants, and is useful for further research, especially 
regarding the effectiveness and safety of its use. In Indonesia, 
there has never been a study on the off-label use of 
anticonvulsants. This study was the first research conducted to 
determine the off-label use of anticonvulsants in a private 
hospital in Java. 
Methods 
This is an observational study with retrospective data collection. Data 
were obtained on the prescription of anticonvulsants in 2014 in a private 
hospital in Java. Indications of the use of anticonvulsants were obtained 
from the medical records of patients who were prescribed 
anticonvulsants. Medical records that could not be traced were excluded. 
The population in this study was made up of all patients (inpatients and 
outpatients) who were prescribed anticonvulsants in a private hospital 
in 2014. 
Off-label use of anticonvulsants was determined by checking the 
diagnoses listed in the medical records on prescribing the 
anticonvulsants. This data was then matched to an approved 
indication by the National Agency of Drug and Food Control (NA-DFC) 
Indonesia in 2014, which is available at www. pionas. pom. go. id. The 
off-label use of anticonvulsants is said to have strong evidence if there 
are some randomized control trial, double-blind, with high-quality 
evidence (further research is very unlikely to change our confidence in 
the estimate of effect)[5]. Descriptive analysis is used to calculate the 
percentage of the off-label use of anticonvulsant. 
RESULTS  
In 2014, 5,310 prescriptions of anticonvulsants were given to 1,316 
patients. The anticonvulsants used in the private hospital are phenytoin 
(PHT), valproate (VPA), gabapentin (GBP), pregabalin (PGB), 
carbamazepine (CBZ), and oxcarbazepine (OXC). The highest used 
anticonvulsant was phenytoin, followed by gabapentin, valproate, 
carbamazepine, pregabalin, and oxcarbazepine. The use of 
anticonvulsants in 2014 can be seen in table 1. 
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Table 1: The use of anticonvulsants in 2014 
No Drug Prescription (n) Patient (n) On-label (%) Off-label (%) 
1 *OXC 213 55 18 (37.72) 37(67.28) 
2 PGB 297 132 72(54.54) 60(45.45) 
3 CBZ 495 117 63(53.85) 54(46.15 
4 PHT 3038 598 373(62.37) 225(37.62) 
5 VPA 569 146 109(74.66) 37(25.34) 
6 GBP 698 268 219(81.72) 49(18.28) 
 Total 5310 1316 854 (64,89%) 462 (35,11%) 
*OXC=oxcarbazepine, PGB=pregabalin, CBZ=carbamazepine, PHT=phenytoin, VPA=valproate, GBP=gabapentin, table 2 shows the percentage of 
anticonvulsant use based on the indications written in the medical records. The indications listed are already indicative of the use off-label of 
anticonvulsants. Most off-label use of anticonvulsants in neurological and psychiatric cases (67.32%). 
 
Table 2: Off-label indication of anticonvulsants 
No The use of anticonvulsants *OXC PGB CBZ PHT VPA GBP Total % 
1 Neurologic and Psychiatric 
disorder 
29 24 40 173 32 13 311 67.32 
2 Rheumatologic disorder 5 8 6 24  19 62 13.42 
3 Renal disorder  20  3  4 27 5.84 
4 Infection diseases 1   8 2 10 21 4.54 
5 Cardiovascular disorder  3 3 7 2 2 17 3.68 
6 Post Herpetic neuropathy 1  3    4 0.87 
7 Oncologic disorder   1 2   3 0.65 
8 Endocrine disorder  2   1  3 0.65 
9 Gastrointestinal disorder 1 1     2 0.43 
10 Dental  1  1   2 0.43 
11 Gynecologic disorder    1   1 0.22 
12 Respiratory disorder    1   1 0.22 
13 Immunologic disorder  1     1 0.22 
14 Other indications   1 5  1 7 1.51 
 Total 37 60 54 225 37 49 462 100 
*OXC=oxcarbazepine, PGB=pregabalin, CBZ=carbamazepine, PHT=phenytoin, VPA=valproate, GBP=gabapentin 
 
DISCUSSION 
The off-label drug use is legalized and clinically accepted. The Food 
and Drug Administration (FDA) as a drug regulatory authority in the 
United States legalizes off-label use under certain conditions. In 
Europe, the regulation of off-label drug prescribing is summarized 
by the European Medicines Agency's (EMA). Off-label prescribing 
provisions include strong scientific evidence or guaranteed safety of 
use by the consensus of professional organizations [6]. In Indonesia, 
there is no clear regulation regarding the off-label drug use. In 2014 
Indonesia implemented a National Health Insurance (Jaminan 
Kesehatan Nasional = JKN) in the form of health insurance for all its 
citizens and was managed by the Social Security Administering 
Agency (Badan Penyelenggara Jaminan Sosial =BPJS) [7]. In the JKN 
system, medicines prescribed that can be financed are medications 
registered by NADFC and listed in the National Formulary (Fornas). 
Fornas is a legal product (law) containing drugs legally registered by 
NADFC. Therefore, off-label drug uses cannot be used by patients 
who enter the JKN scheme. Even if doctors prescribe the drugs listed 
in the fornas with indications that are not or have not been approved 
by NADFC, of course, the drugs cannot be financed, or it is the 
responsibility of the RS to finance [8]. The results of this study 
indicate the presence of off-label drug use of anticonvulsants in 
Indonesia. The known evidence for the off-label drug use of 
anticonvulsants are as follows:  
Table 1 show that the highest percentage of off-label use of 
anticonvulsants was for oxcarbazepine, although OXC has the lowest 
number of prescriptions. The off-label use of OXC is common in cases 
of trigeminal neuralgia. Oxcarbazepine (10, 11-dihydro-10-oxo-
5Hdibenz (b. f) azepine-5-carboxamide) is a keto analogue of 
carbamazepine. OXC has the same mechanism as carbamazepine, as 
a sodium channel modulator, making it effective for epilepsy and 
trigeminal neuralgia. OXC is safer than CBZ with low risk of allergies 
and drug interactions [5]. The use of OXC on trigeminal neuralgia 
has been investigated by Gomez-Arguelles et al. (2008) with the 
results demonstrating a significant reduction in the frequency of 
pain and it was well tolerated by patients. OXC is recommended in 
patients who do not respond to CBZ. Carrazana found that the 
evidence supporting the use of OXC for trigeminal neuralgia is strong 
[9, 10]. The use of OXC for other indications such as painful diabetic 
neuropathy, post-herpetic neuralgia, painful paroxysmal symptoms 
in multiple sclerosis, tremor, and migraine has already been 
investigated with a poor-moderate evidence level [5, 11–14]. In this 
study, the use of OXC in trigeminal neuralgia is categorized as off-
label use because the distribution license in Indonesia does not 
include an indication for OXC in trigeminal neuralgia. 
The second most frequent off-label use of anticonvulsants is for 
pregabalin, widely used in patients with stroke and renal disorders. 
It is given to stroke patients for central post-stroke pain. The use of 
pregabalin in renal impairment is expected to prevent seizures (PGB 
is not the main therapy for preventing seizure). Pregabalin (3-
isobutyl-ᵧ aminobutyric acid) is a GABA analogue that does not 
function GABA neurotransmitter. Pregabalin is not binding to 
GABAA and GABAB. Pharmacologically, pregabalin related bonding 
results in the presynaptic alpha-2-delta subunit of Ca2+channels [15]. 
According to Finnerup and Jensen (2007), there are two studies with 
randomized placebo-controlled trials on the use of pregabalin for 
neuropathic pain post stroke. Results from both studies showed that 
PGB is effective for central neuropathic post-stroke pain, and may 
improve the level of anxiety and sleep disorders [16]. Many studies 
have been conducted on the analgesic effect of pregabalin including 
pregabalin for acute and chronic pain, evaluation of safety and 
efficacy of pregabalin in geriatric patients, pregabalin for DPN and 
PHN, pregabalin for bone cancer pain, pregabalin for postoperative 
pain [17–20]. The study of the adverse effects of pregabalin as an 
analgesic has also been done. The side effects include somnolence, 
dizziness, peripheral oedema, and dry mouth [21]. The FDA has 
licensed the use of pregabalin for the treatment of neuropathic pain 
associated with diabetic peripheral neuropathy (DPN), post-herpetic 
neuralgia (PHN), and adjunctive therapy in an adult partial seizure. 
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The FDA has not given permission for the treatment of generalized 
anxiety disorder (GAD) [15]. The distribution license in Indonesia is 
for peripheral neuropathic pain and adjunctive therapy for partial 
seizures with or without secondary generalization. 
In this study, the off-label use of carbamazepine was found for 
central post-stroke pain. Other users with a smaller percentage were 
for DPN, PHN, herniated nucleus pulposus (HNP), and joint pain. The 
mechanisms of carbamazepine for neuropathic pain is by blocking 
the sodium channels that can reduce the excitability of nerve cells 
[22]. The mechanism for reducing nociceptive pain is estimated from 
the ability of carbamazepine to intervene on ᵧ -aminobutyric acid 
(GABA)-ergic and somatostatinergic systems. Other mechanisms, 
with low evidence, are by blocking calcium channels and excitatory 
amino acid [23]. Research on the use of carbamazepine in other than 
trigeminal neuralgia has lacked evidence. Regarding central post-
stroke pain, there is only one study, while on DPN there is some 
research but also a low evidence level, similarly for PHN [24, 25]. 
Carbamazepine in Indonesia has a distribution license for the 
prophylaxis of indications of manic-depressive disorder that is not 
responsive to lithium, all types of epilepsy, except petit mal, and 
trigeminal neuralgia. 
The off-label use of phenytoin occurs in the case of petit mal epilepsy 
or absence seizures. Phenytoin is an old anticonvulsant and is widely 
used to control seizures by stabilizing the mechanism of sodium 
channels. Phenytoin is also known to be used in anxiety and mood 
stabilizing. Phenytoin and CBZ were the anticonvulsants that were 
first examined in trigeminal neuralgia [26]. Some use of phenytoin in 
neuropathic pain has less powerful evidence or no evidence [27]. 
Phenytoin is contraindicated in petit mal because it can cause 
seizures and is ineffective [28]. The NA-DFC distribution license 
granted for phenytoin includes therapy for all types of epilepsy, 
except for petit mal and status epilepticus. 
This study found that valproate was used in cephalgia, vertigo, 
syncope, and schizophrenia. Valproate is thought to have a GABA-ergic 
neurotransmission influence mechanism and also the blockade of the 
sodium channels. Increased GABA levels and cell membrane stability 
are thought to reduce pain signals in the brain [29]. A review by 
Vargas-Espinosa et al. mentions the use of valproate for PHN and 
makes a recommendation for a high-quality randomized controlled 
trial [29]. Studies have been conducted on valproate for indications 
other than epilepsy, on migraine, alcohol dependence, bipolar 
disorders, fibromyalgia, and schizophrenia with low evidence [29–31]. 
In previous studies, gabapentin is an anticonvulsant that is often 
used off-label. During its development, gabapentin research on 
indications outside epilepsy was conducted with strong evidence, so 
the industry finally registered gabapentin to the drug and food 
authority bodies, so that gabapentin became on-label for any 
neuropathic pain. Gabapentin has strong anticonvulsant and 
analgesic effects through the GABA-ergic transmission modulation 
mechanism. Another mechanism is the blockade of the sodium 
channels [32]. The off-label use of gabapentin in this study was 
found for nociceptive pain in rheumatism, joint pain, osteoarthritis, 
phlebitis, and fracture. Gabapentin in nociceptive pain has been 
studied in post-operative pain management with good efficacy, and 
in benign nociceptive pain [32, 33]. In Indonesia, the gabapentin 
permit allows adjunctive therapy for partial epilepsy with or without 
a generalized seizure, which cannot be controlled with other 
antiepilepsy medication, and for neuropathic pain. 
The indication of the off-label use of anticonvulsants can be seen in 
table 2. The most common off-label use of anticonvulsants is in 
neurological and psychiatric, then in rheumatic and renal disorder. 
In neurological cases, off-label use occurs in cases of neuropathy 
pain, stroke, trigeminal neuralgia, cephalgia, and petit mal. Research 
conducted by Jena et al. in 2013-2014 mentions several 
anticonvulsants prescribed for neuropathic pain, namely 
carbamazepine, gabapentin, pregabalin, lamotrigine, oxcarbazepine, 
topiramate, and valproate [34]. Some anticonvulsants prescribed for 
neuropathic pain are usually used in the long term. It should be 
noted, because based on research Varghese et al. the chronic use of 
anticonvulsant cause osteoporosis and anaemia significantly [35]. 
While in rheumatic disease, anticonvulsants are used in 
osteoarthritis, fracture, and joint pain. In the case of renal disorders, 
the use of anticonvulsants is not clear, possibly associated with 
preventing seizure in hemodialysis patients. Of 462 off-label 
prescriptions, only 13 (2.81%) had strong evidence, namely, OXC in 
trigeminal neuralgia. While the remaining 449 (97.19%) have low 
evidence or lack of evidence. From the study, anticonvulsants were 
known to cause adverse drug reaction (ADR) by 36% of 132 ADR 
events. ADR was found in carbamazepine (16.6%) and pregabalin 
(9.8%). Common ADRs are nausea, dizziness, and drowsiness [34]. 
Limitation 
This was a retrospective study at one private hospital in Java, and 
the result may not be generalizable for another hospital or another 
country. This study could not determine why physicians prescribed 
a drug for a particular indication. However, the findings provide 
important information for future research, because nearly all the off-
label uses of anticonvulsants lack evidence. 
CONCLUSION 
The off-label use of anticonvulsants occurred in one-third of patients 
receiving prescriptions of anticonvulsants, even though for most of 
them there was a lack of evidence. More attention must be paid to 
the efficacy and risk of side effects of the drug used.  
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